These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30312541)

  • 1. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.
    Norum HM; Michelsen AE; Lekva T; Arora S; Otterdal K; Olsen MB; Kong XY; Gude E; Andreassen AK; Solbu D; Karason K; Dellgren G; Gullestad L; Aukrust P; Ueland T
    Am J Transplant; 2019 Apr; 19(4):1050-1060. PubMed ID: 30312541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
    Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
    ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
    Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).
    Lee KS; Kim H; Lee SH; Choi DJ; Yoon M; Jeon ES; Choi JO; Kang J; Lee HY; Jung SH; Oh J; Kang SM; Lee SY; Ju MH; Kim JJ; Kim MS; Cho HJ
    Transpl Int; 2024; 37():11878. PubMed ID: 38644935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).
    Relbo Authen A; Grov I; Karason K; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Dellgren G; Solbu D; Arora S; Andreassen AK; Gullestad L
    Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients.
    Watanabe T; Seguchi O; Nishimura K; Fujita T; Murata Y; Yanase M; Sato T; Sunami H; Nakajima S; Hisamatsu E; Sato T; Kuroda K; Hieda M; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
    Int J Cardiol; 2016 Jan; 203():307-14. PubMed ID: 26523360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation.
    Mirza K; Gustafsson F; Gullestad L; Arora S; Andersen C
    Transpl Immunol; 2016 Sep; 38():75-7. PubMed ID: 27260644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial.
    Arora S; Erikstad I; Ueland T; Sigurdardottir V; Ekmehag B; Jansson K; Eiskjaer H; Bøtker HE; Mortensen SA; Saunamaki K; Gude E; Ragnarsson A; Solbu D; Aukrust P; Gullestad L
    Am J Transplant; 2012 Oct; 12(10):2700-9. PubMed ID: 22958738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
    Gude E; Gullestad L; Andreassen AK
    Curr Opin Organ Transplant; 2017 Jun; 22(3):198-206. PubMed ID: 28463861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function.
    Grimm K; Lehner A; Fernandez Rodriguez S; Orban M; Fischer M; Rosenthal LL; Jakob A; Haas NA; Dalla Pozza R; Kozlik-Feldmann R; Ulrich SM
    Clin Transplant; 2021 Mar; 35(3):e14191. PubMed ID: 33315277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
    Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
    Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART.
    Potena L; Pellegrini C; Grigioni F; Amarelli C; Livi U; Maccherini M; Masciocco G; Faggian G; Lilla Della Monica P; Gerosa G; Marraudino N; Corda M; Boffini M;
    Transplantation; 2018 Mar; 102(3):493-501. PubMed ID: 28930797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
    Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
    Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A; Wang SS; Epailly E; Barten MJ; Sigurdardottir V; Segovia J; Varnous S; Turazza FM; Potena L; Lehmkuhl HB
    Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.